Weiming Penguin Honors | Dr. Zou Xiaoliang Appointed Vice President of the Eighth Council of the Business School MBA Management Committee of the Renmin University of China Alumni Association
Article images may contain Chinese text.
At the inaugural meeting of the Eighth Council of the Renmin University of China Business School MBA Alumni Association on June 28, Dr. Zou Xiaoliang, founder and CEO of Weiming Penguin, was formally appointed vice president of the Eighth Council in recognition of his outstanding contributions to digital transformation in the pharmaceutical industry and extensive industry experience. School Party Secretary Xuan Tianying and Dean Yi Jingtao presented the appointment certificate. This not only represents strong recognition of Dr. Zou’s personal achievements but also highlights Weiming Penguin’s far-reaching influence in integrating the pharmaceutical industry with the internet.

Appointment Ceremony for Vice Presidents of the Eighth Council
Dr. Zou Xiaoliang is a seasoned expert with nearly two decades of work experience spanning university education, the internet, AI, and industry digital intelligence. He is currently CEO of Weiming Penguin, an alumnus of Renmin University of China, and holds a doctoral degree (DBA) from Peking University. He is also a visiting professor at Inner Mongolia University of Technology, an expert with Caixin’s think tank, and a vice president of the China Association of Pharmaceutical Commerce. He has been recognized as a Beijing Haiying Talent and named an “Emerging Figure in Pharmaceutical Distribution on the 40th Anniversary of Reform and Opening Up” by the China Association of Pharmaceutical Commerce. Previously, he served as a senior director in Alibaba’s Business Intelligence Department, vice president of online media products and business operations at Tencent, and a faculty member at Inner Mongolia University of Technology.

In 2015, Dr. Zou Xiaoliang founded Weiming Penguin, a leading company dedicated to providing pharmaceutical digital intelligence solutions. Using big data technologies, AI technologies, and technology-based solutions to drive digital transformation at pharmaceutical companies, Weiming Penguin has become a leading player in the industry after nearly nine years of development, serving more than 100 domestic and foreign-invested pharmaceutical and medical device companies.
Dr. Zou Xiaoliang and his team have made significant achievements in digital transformation in the pharmaceutical industry. Their independently developed DIG digital intelligence solution portfolio has effectively addressed pharmaceutical companies’ data challenges, helping them digitize their organizations and business operations and turn data into assets. Meanwhile, Weiming Penguin’s mature AI applications have provided pharmaceutical companies with precise business insights and strong support for strategic adjustments. These innovations have not only earned widespread recognition in the pharmaceutical market but also set a new benchmark for the industry’s digital intelligence upgrades.
Renmin University of China Business School has consistently pursued its mission of “contributing Chinese management wisdom and cultivating global leaders.” It is committed to becoming “a world-class business school with the deepest understanding of management in China” and continues to lead high-quality development in business education. Since it became a pioneer in admitting and educating China’s own MBA students in 1990, the school’s MBA program has trained more than 10,000 business leaders and management professionals over 34 years, who now hold leadership positions across a wide range of fields. The Business School’s MBA Alumni Association aims to bring alumni together, support their development, study Chinese management wisdom, and build a diverse learning community that sets a benchmark for MBA communities in China. On being elected vice president of the Eighth Council of the MBA Alumni Association, Dr. Zou Xiaoliang said: “I am deeply honored to take on this role. It recognizes not only my own work but also the efforts of the Weiming Penguin team and our work toward digital transformation in the pharmaceutical industry. Looking ahead, I will continue to uphold our mission of ‘Weiming Penguin, Connecting Health,’ work together with fellow alumni and colleagues at pharmaceutical companies, and continue contributing what I can in our respective roles.”
